Description
IMPLEMENTING EO 14398 DEI DISCRIMINATION
Base award description: NEW AWARD FOR BEVACIZUMAB INJECTIONS WITH PFIZER, INC. ORDERING PERIOD IS AUGUST 13, 2025 TO AUGUST 12, 2026 WITH FOUR ONE-YEAR OPTIONS
Modification chain · 5 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2025-04-11+$0= $0
- Mod P000012025-11-21+$0= $0
- Mod P000022026-01-12+$0= $0
- Mod P000032026-06-30+$0= $0
- Mod P000042026-08-27+$0= $0
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2025-04-11 | +$0 | $0 | NEW AWARD FOR BEVACIZUMAB INJECTIONS WITH PFIZER, INC. ORDERING PERIOD IS AUGUST 13, 2025 TO AUGUST 12, 2026 W… |
| Mod P00001· OTHER ADMINISTRATIVE ACTION | 2025-11-21 | +$0 | $0 | THIS MODIFICATION IS ISSUED TO INCORPORATE 2026 FEDERAL CEILING PRICES UNDER CONTRACT 36E79725D0030. |
| Mod P00002· ADD SUBCONTRACTING PLAN | 2026-01-12 | +$0 | $0 | THIS MODIFICATION IS ISSUED TO INCORPORATE PFIZER INC. 2026 SUBCONTRACTING PLAN FOR NC 36E79725D0030. |
| Mod P00003· EXERCISE AN OPTION | 2026-06-30 | +$0 | $0 | THIS MODIFICATION IS ISSUED TO EXERCISE OPTION YEAR 1 WITH PFIZER INC. FOR NC 36E79725D0030. |
| Mod P00004· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2026-08-27 | +$0 | $0 | IMPLEMENTING EO 14398 DEI DISCRIMINATION |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI MHBQULRMEEJ5)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36E79725D0032 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2025 |
| 36C77024P0393 | NATIONAL CMOP OFFICE (36C770) · 6505 · DRUGS AND BIOLOGICALS | $243,101 | FY2024 |
| 36F79724D0130 | NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2024 |
| 36C25024F0047 | 250-NETWORK CONTRACT OFFICE 10 (36C250) · 6505 · DRUGS AND BIOLOGICALS | $215,205 | FY2024 |
| 36E79723A0023 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2023 |
| 36E79720D0067 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2020 |
Other recipients under 6505 from NAC PHARMACEUTICALS (36E797) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36E79726A0025 | CHIESI USA INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0024 | NEUROTECH PHARMACEUTICALS, INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0023 | TAKEDA PHARMACEUTICALS AMERICA, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726D0041 | GOLDEN STATE MEDICAL SUPPLY, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0022 | AURINIA PHARMA US INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_IDV_36E79725D0030_3600 · retrieved 2026-09-26.